Holly LaDuca

4.9k total citations · 1 hit paper
64 papers, 2.1k citations indexed

About

Holly LaDuca is a scholar working on Genetics, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Holly LaDuca has authored 64 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Genetics, 26 papers in Pathology and Forensic Medicine and 21 papers in Cancer Research. Recurrent topics in Holly LaDuca's work include BRCA gene mutations in cancer (39 papers), Genetic factors in colorectal cancer (26 papers) and Cancer Genomics and Diagnostics (21 papers). Holly LaDuca is often cited by papers focused on BRCA gene mutations in cancer (39 papers), Genetic factors in colorectal cancer (26 papers) and Cancer Genomics and Diagnostics (21 papers). Holly LaDuca collaborates with scholars based in United States, Australia and Türkiye. Holly LaDuca's co-authors include Jill S. Dolinsky, Elizabeth Chao, Rachel McFarland, Tina Pesaran, Fergus J. Couch, David E. Goldgar, Shuwei Li, Hermela Shimelis, Chunling Hu and Eric C. Polley and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Holly LaDuca

59 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

2017 393 citations Fergus J. Couch, Chunling Hu et al. JAMA Oncology profile →

Peers

Holly LaDuca

GENET

PFM

ONCOL

Edward D. Esplin United States

Carrie Snyder United States

Rita K. Schmutzler Germany

Leigha Senter United States

Rebecca Nagy United States

Joanne L. Blum United States

Joan H. Marks United States

E. von Schoultz Sweden

Matthias W. Beckmann Germany

Paul A. Russell United Kingdom

Edward D. Esplin United States

Holly LaDuca

789 ×0.6

GENET

866 ×1.1

539 ×0.8

367 ×0.5

PFM

522 ×1.1

ONCOL

Citations per year, relative to Holly LaDuca Holly LaDuca (= 1×) peers Edward D. Esplin

Countries citing papers authored by Holly LaDuca

Since Specialization

Citations

This map shows the geographic impact of Holly LaDuca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly LaDuca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly LaDuca more than expected).

Fields of papers citing papers by Holly LaDuca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly LaDuca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly LaDuca. The network helps show where Holly LaDuca may publish in the future.

Co-authorship network of co-authors of Holly LaDuca

This figure shows the co-authorship network connecting the top 25 collaborators of Holly LaDuca. A scholar is included among the top collaborators of Holly LaDuca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holly LaDuca. Holly LaDuca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bychkovsky, Brittany, Min‐Tzu Lo, Amal Yussuf, et al.. (2023). Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception. Breast Cancer Research and Treatment. 200(1). 63–72.

Horton, Carolyn, Lily Hoang, Heather Zimmermann, et al.. (2023). Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. JAMA Oncology. 10(2). 212–212. 14 indexed citations

Iversen, Edwin S., Steven N. Hart, Kun Y. Lee, et al.. (2022). An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance. npj Genomic Medicine. 7(1). 35–35. 4 indexed citations

Bychkovsky, Brittany, Nihat Buğra Ağaoğlu, Carolyn Horton, et al.. (2022). Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2. JAMA Oncology. 8(11). 1598–1598. 48 indexed citations

Hernandez, Felicia, et al.. (2021). Classification of the canonical splice alteration MUTYH c.934-2A > G is likely benign based on RNA and clinical data. Molecular Case Studies. 8(1). a006152–a006152. 1 indexed citations

Bychkovsky, Brittany, Min‐Tzu Lo, Amal Yussuf, et al.. (2021). Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics. Cancer. 128(6). 1275–1283. 13 indexed citations

Richardson, Marcy E., Chunling Hu, Kun Y. Lee, et al.. (2021). Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. The American Journal of Human Genetics. 108(3). 458–468. 29 indexed citations

Wu, Yishuo, Hongjie Yu, Shuwei Li, et al.. (2020). Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology. 3(2). 224–230. 38 indexed citations

Black, Mary Helen, Shuwei Li, Holly LaDuca, et al.. (2020). Validation of a prostate cancer polygenic risk score. The Prostate. 80(15). 1314–1321. 19 indexed citations

10.

Tian, Yuan, Patrick Reineke, Aaron J. Stuenkel, et al.. (2020). Diagnosing hereditary cancer predisposition in men with prostate cancer. Genetics in Medicine. 22(9). 1517–1523. 32 indexed citations

11.

Xicola, Rosa M., Shuwei Li, Rachid Karam, et al.. (2019). Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. Journal of Medical Genetics. 56(12). 838–843. 75 indexed citations

12.

Rana, Huma Q., Lily Hoang, Holly LaDuca, et al.. (2019). Genotype–phenotype associations among panel-based TP53+ subjects. Genetics in Medicine. 21(11). 2478–2484. 18 indexed citations

13.

Milam, Michael R., Shuwei Li, Amal Yussuf, et al.. (2019). Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing. Gynecologic Oncology. 152(3). 612–617. 11 indexed citations

14.

Powis, Zöe, Carin R. Espenschied, Holly LaDuca, et al.. (2018). Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent. Cancer Genetics. 224-225. 12–20. 3 indexed citations

15.

LaDuca, Holly, Mary Helen Black, Dajun Qian, et al.. (2018). Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort. Familial Cancer. 18(2). 197–201. 17 indexed citations

16.

Stanich, Peter P., Rachel Pearlman, Alice Hinton, et al.. (2018). Prevalence of Germline Mutations in Polyposis and Colorectal Cancer–Associated Genes in Patients With Multiple Colorectal Polyps. Clinical Gastroenterology and Hepatology. 17(10). 2008–2015.e3. 45 indexed citations

17.

LaDuca, Holly, Kelly D. Farwell, Huy Gia Vuong, et al.. (2017). Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels. PLoS ONE. 12(2). e0170843–e0170843. 79 indexed citations

18.

Leedom, Tracey P., Holly LaDuca, Rachel McFarland, et al.. (2016). Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers. Cancer Genetics. 209(9). 403–407. 36 indexed citations

19.

LaDuca, Holly, Aaron J. Stuenkel, Jill S. Dolinsky, et al.. (2014). Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genetics in Medicine. 16(11). 830–837. 237 indexed citations

20.

Burton, Barbara K., et al.. (2010). Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Molecular Genetics and Metabolism. 101(2-3). 110–114. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact